Advertisement

Cardiac and Metabolic Effects of Anabolic-Androgenic Steroid Abuse on Lipids, Blood Pressure, Left Ventricular Dimensions, and Rhythm

      Recent surveys and reports suggest that many athletes and bodybuilders abuse anabolic-androgenic steroids (AAS). However, scientific data on the cardiac and metabolic complications of AAS abuse are divergent and often conflicting. A total of 49 studies describing 1,467 athletes were reviewed to investigate the cardiovascular effects of the abuse of AAS. Although studies were typically small and retrospective, some associated AAS abuse with unfavorable effects. Otherwise healthy young athletes abusing AAS may show elevated levels of low-density lipoprotein and low levels of high-density lipoprotein. Although data are conflicting, AAS have also been linked with elevated systolic and diastolic blood pressure and with left ventricular hypertrophy that may persist after AAS cessation. Finally, in small case studies, AAS abuse has been linked with acute myocardial infarction and fatal ventricular arrhythmias. In conclusion, recognition of these adverse effects may improve the education of athletes and increase vigilance when evaluating young athletes with cardiovascular abnormalities.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hoberman J.
        • Yesalis C.E.
        The history of synthetic testosterone.
        Sci Am. 1995; 272: 76-81
        • Saseen J.
        • MacLaughlin E.J.
        Appetite stimulants and anabolic steroid therapy for AIDS wasting.
        AIDS Read. 1999; 9 (401–402, 407): 398
        • Basaria S.
        • Wahlstrom J.T.
        • Dobs A.S.
        Clinical review 138: anabolic-androgenic steroid therapy in the treatment of chronic diseases.
        J Clin Endocr Metab. 2001; 86: 5108-5117
        • Denham B.
        Sports Illustrated, the mainstream press and the enactment of drug policy in major league baseball.
        Journalism. 2004; 5: 51-68
      1. Associated Press. Steroid, other drugs found in bodies of wrestler, wife, son.
        (Accessed on June 1, 2010)
        • Clark A.
        Behavioral and physiological responses to anabolic-androgenic steroids.
        Neurosci Biobehav Rev. 2003; 27: 413-436
        • Parkinson A.
        • Evans N.A.
        Anabolic androgenic steroids: a survey of 500 users.
        Med Sci Sport Exer. 2006; 38: 644-651
        • Lukas S.
        Current perspectives on anabolic-androgenic steroid abuse.
        Trends Pharmacol Sci. 1993; 14: 61-68
        • United States Department of Justice, Drug Enforcement Administration. Title 21 United States Code (USC) Controlled Substances Act
        (Accessed on June 1, 2010)
        • Mitchell G.
        Report to the commissioner of baseball of an independent investigation into the illegal use of steroids and other performance enhancing substances by players in major league baseball.
        (Accessed on June 1, 2010)
        • Maravelias C.
        • Dona A.
        • Stefanidou M.
        • Spiliopoulou C.
        Adverse effects of anabolic steroids in athletes.
        Toxicol Lett. 2005; 158: 167-175
        • Kutscher E.
        • Lund B.C.
        • Perry P.J.
        Anabolic steroids: a review for the clinician.
        Sports Med. 2002; 32: 285-296
        • Sader M.A.
        • Griffiths K.A.
        • McCredie R.J.
        • Handelsman D.J.
        • Celermajer D.S.
        Androgenic anabolic steroids and arterial structure and function in male bodybuilders.
        J Am Coll Cardiol. 2001; 37: 224-230
        • Lenders J.W.
        • Demacker P.N.
        • Vos J.A.
        • Jansen P.L.
        • Hoitsma A.J.
        • Van't Laar A.
        • Thien T.
        Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur bodybuilders.
        Int J Sports Med. 1988; 9: 19-23
        • Dickerman R.
        • Schaller F.
        • Zachariah N.Y.
        • McConathy W.J.
        Left ventricular size and function in elite bodybuilders using anabolic steroids.
        Clin J Sport Med. 1997; 7: 90-93
        • Yesalis C.
        • Kennedy N.J.
        • Kopstein A.N.
        • Bahrke M.S.
        Anabolic-androgenic steroid use in the United States.
        JAMA. 1993; 270: 1217-1221
        • Henkin Y.
        • Como J.A.
        • Oberman A.
        Secondary dyslipidemia.
        JAMA. 1992; 267: 961-968
        • Wood R.
        Anabolic steroids: a fatal attraction?.
        J Neuroendrocrinol. 2006; 18: 227-228
        • Lenehan P.
        • Bellis M.
        • McVeigh J.
        A study of anabolic steroid use in the North West of England.
        J Perf Enh Drugs. 1996; 1: 57-70
        • Tricker R.
        • Cook D.
        The incidence of anabolic steroid use among competitive bodybuilders.
        J Drug Educ. 1989; 19: 313-325
        • Curry L.
        • Wagman D.F.
        Qualitative description of the prevalence and use of anabolic androgenic steroids by United States powerlifters.
        Percep Motor Skill. 1999; 88: 224-233
        • Petersson A.
        • Garle M.
        • Granath F.
        • Thiblin I.
        Morbidity and mortality in patients testing positively for the presence of anabolic androgenic steroids in connection with receiving medical care.
        Drug Alcohol Depen. 2006; 81: 215-220
        • Thiblin I.
        • Lindquist O.
        • Rajs J.
        Cause and manner of death among users of anabolic androgenic steroids.
        J Forensic Sci. 2000; 45: 16-23
        • Parssinen M.
        • Kujala U.
        • Vartiainen E.
        • Sarna S.
        • Seppala T.
        Increased premature mortality of competitive powerlifters suspected to have used anabolic agents.
        Int J Sports Med. 2000; 21: 225-227
        • Parssinen M.
        • Seppala T.
        Steroid use and long-term health risks in former athletes.
        Sports Med. 2002; 2002: 83-84
        • Bergink E.
        • Geelen J.A.A.
        • Turpijn E.W.
        Metabolism and receptor binding of nandrolone and testosterone under in vitro and in vivo conditions.
        Acta Endocrinol. 1985; 110: 31-37
        • Rosano G.M.
        • Cornoldi A.
        • Fini M.
        Effects of androgens on the cardiovascular system.
        J Endocrinol Invest. 2005; 28: 32-38
        • Wynne F.
        • Khalil R.A.
        Testosterone and coronary vascular tone: implications in coronary artery disease.
        J Endocrinol Invest. 2003; 26: 181-186
        • Ferrer M.
        • Encabo A.
        • Marin J.
        • Balfagon G.
        Chronic treatment with anabolic steroid, nandrolone, inhibits vasodilator responses in rabbit aorta.
        Eur J Pharmacol. 1994; 252: 233-241
        • Zaugg M.
        • Jamali N.Z.
        • Lucchinetti E.
        • Xu W.
        • Alam M.
        • Shafiq S.A.
        • Siddiqui M.A.
        Anabolic- androgenic steroids induce apoptotic cell death in adult rat ventricular myocytes.
        J Cell Physiol. 2001; 187: 90-95
        • Kai H.
        • Muraishi A.
        • Sugiu Y.
        • Nishi H.
        • Seki Y.
        • Kuwahara F.
        • Kimura A.
        • Kato H.
        • Imaizumi T.
        Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy.
        Circ Res. 1998; 83: 594-601
        • Lieberherr M.
        • Grosse B.
        Androgens increase intracellular calcium concentration and inositol 1,4,5-triphosphate and diacylglycerol formation via a pertussis toxin-sensitive G-protein.
        J Biol Chem. 1994; 269: 7217-7223
        • Kroemer G.
        • Dallaporta B.
        • Resche-Rigon M.
        The mitochondrial death/life regulator in apoptosis and necrosis.
        Annu Rev Physiol. 1998; 60: 619-642
        • Maron B.
        • Roberts W.C.
        • McAllister H.A.
        • Rosing D.R.
        • Epstein S.E.
        Sudden death in young athletes.
        Circulation. 1980; 62: 218-229
        • Kennedy C.
        • Lawrence C.
        Anabolic steroid abuse and cardiac death.
        Med J Aust. 1993; 158: 346-348
        • Lajarin F.
        • Zaragoza R.
        • Tovar I.
        • Martinez-Hernandez P.
        Evolution of serum lipids in two male bodybuilders using anabolic steroids.
        Clin Chem. 1996; 42: 970-972
        • McKillop G.
        • Ballantyne D.
        Lipoprotein analysis in bodybuilders.
        Int J Cardiol. 1987; 17: 281-288
        • Palatini P.
        • Giada F.
        • Garavelli G.
        • Sinisi F.
        • Mario L.
        • Michieletto M.
        • Baldo-Enzi G.
        Cardiovascular effects of anabolic steroids in weight-trained subjects.
        J Clin Pharmacol. 1996; 36: 1132-1140
        • Baldo-Enzi G.
        • Giada F.
        • Zuliani G.
        • Baroni L.
        • Vitale E.
        • Enzi G.
        • Magnanini P.
        • Fellin R.
        Lipid and apoprotein modifications in body builders during and after self-administration of anabolic steroids.
        Metabolism. 1990; 39: 203-208
        • Fröhlich J.
        • Kullmer T.
        • Urhausen A.
        • Bergmann R.
        • Kindermann W.
        Lipid profile of body builders with and without self-administration of anabolic steroids.
        Eur J Appl Physiol. 1989; 59: 98-103
        • Hartgens F.
        • Rietjens G.
        • Keizer H.A.
        • Kuipers H.
        • Wolffenbuttel B.
        Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a).
        Br J Sport Med. 2004; 38: 253-259
        • Lane H.
        • Grace F.
        • Smith J.C.
        • Morris K.
        • Cockcroft J.
        • Scanlon M.F.
        • Davies J.S.
        Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids.
        Eur J Clin Invest. 2006; 36: 483-488
        • Urhausen A.
        • Albers T.
        • Kindermann W.
        Are the cardiac effects of anabolic steroid abuse in strength athletes reversible?.
        Heart. 2004; 90: 496-501
        • Zuliani U.
        • Bernardini B.
        • Catapano A.
        • Campana M.
        • Cerioli G.
        • Spattini M.
        Effects of anabolic steroids, testosterone, and HGH on blood lipids and echocardiographic parameteres in body builders.
        Int J Sports Med. 1989; 10: 62-66
        • Glazer G.
        Atherogenic effects of anabolic steroids on serum lipid levels.
        Arch Intern Med. 1991; 151: 1925-1933
        • McNutt R.A.
        • Ferenchick G.S.
        • Kirlin P.C.
        • Hamlin N.J.
        Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids.
        Am J Cardiol. 1988; 62: 164
        • Nieminen M.
        • Ramo M.P.
        • Viitasalo M.
        • Heikkila P.
        • Karjalainen J.
        • Mantysaari M.
        • Heikkila J.
        Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters.
        Eur Heart J. 1996; 17: 1576-1583
        • Yeater R.
        • Reed C.
        • Ullrich I.
        • Morise A.
        • Borsch M.
        Resistance trained athletes using or not using anabolic steroids compared to runners: effects on cardiorespiratory variables, body composition, and plasma lipids.
        Br J Sport Med. 1996; 30: 11-14
        • Bowman S.
        Anabolic steroids and infarction.
        BMJ. 1990; 300: 750
        • Pope H.J.
        • Katz D.L.
        Psychiatric and medical effects of anabolic-androgenic steroid use.
        Arch Gen Psychiatry. 1994; 51: 375-382
        • Labib M.
        • Haddon A.
        The adverse effects of anabolic steroids on serum lipids.
        Ann Clin Biochem. 1996; 33: 263-264
        • Király C.
        Androgenic-anabolic steroid effects on serum and skin surface lipids, on red cells, and on liver enzymes.
        Int J Sports Med. 1988; 9: 249-252
        • Thompson P.
        • Cullinane E.M.
        • Sady S.P.
        • Chenevert C.
        • Saritelli A.L.
        • Sady M.A.
        • Herbert P.N.
        Contrasting effects of testosterone and stanozolol on serum lipoprotein levels.
        JAMA. 1989; 261: 1165-1168
        • Malarkey W.
        • Strauss R.H.
        • Leizman D.J.
        • Liggett M.
        • Demers L.M.
        Endocrine effects in female weight lifters who self-administer testosterone and anabolic steroids.
        Am J Obstet Gynecol. 1991; 165: 1385-1390
        • Urhausen A.
        • Torsten A.
        • Wilfried K.
        Reversibility of the effects on blood cells, lipids, liver function and hormones in former anabolic-androgenic steroid abusers.
        J Steroid Biochem. 2003; 84: 369-375
        • O'Connor J.S.
        • Baldini F.D.
        • Skinner J.S.
        • Einstein M.
        Blood chemistry of current and previous anabolic steroid users.
        Mil Med. 1990; 155: 72-75
        • Hislop M.
        • St. Clair Gibson A.
        • Lambert M.I.
        • Noakes T.D.
        • Marals A.D.
        Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle size and lipoprotein(a) in men.
        Atherosclerosis. 2001; 159: 425-432
        • Bagchus W.
        • Smeets J.M.
        • Verheul H.A.
        • De Jager-Van Der Veen S.M.
        • Port A.
        • Guert T.
        Pharmacokinetic evaluation of three different intramuscular doses of nandrolone decanoate: analysis of serum and urine samples in healthy men.
        J Clin Endocr Metab. 2005; 90: 2624-2630
        • Di Bello V.
        • Giorgi D.
        • Bianchi M.
        • Bertini A.
        • Caputo M.T.
        • Valenti G.
        • Furioso O.
        • Alessandri L.
        • Paterni M.
        • Giusti C.
        Effects of anabolic-androgenic steroids on weight-lifters' myocardium: an ultrasonic videodensitometric study.
        Med Sci Sport Exer. 1999; 31: 514-521
        • Riebe D.
        • Fernhall B.
        • Thompson P.D.
        The blood pressure response to exercise in anabolic steroid users.
        Med Sci Sport Exer. 1992; 24: 633-637
        • D'Andrea A.
        • Caso P.
        • Salerno G.
        • Scarafile R.
        • De Corato G.
        • Mita C.
        • Di Salvo G.
        • Severino S.
        • Cuomo S.
        • Liccardo B.
        • Esposito N.
        • Calabro R.
        Left ventricular early myocardial dysfunction after chronic abuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis.
        Br J Sport Med. 2006; 41: 149-155
        • De Piccoli B.
        • Giada F.
        • Benettin A.
        • Sartori F.
        • Piccolo E.
        Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function.
        Int J Sports Med. 1991; 12: 408-412
        • Hartgens F.
        • Cheriex E.C.
        • Kuipers H.
        Prospective echocardiographic assessment of anabolic steroids effects on cardiac structure and function in strength athletes.
        Int J Sports Med. 2003; 24: 344-351
        • Karila T.
        • Karjalainen J.E.
        • Mantysaari M.J.
        • Viitasalo M.T.
        • Seppala T.A.
        Anabolic androgenic steroids produce dose-dependent increase in left ventricular mass in power athletes, and this effect is potentiated by concomitant use of growth hormone.
        Int J Sports Med. 2003; 24: 337-343
        • Krieg A.
        • Scharhag J.
        • Albers T.
        • Kindermann W.
        • Urhausen A.
        Cardiac tissue Doppler in steroid users.
        Int J Sports Med. 2007; 28: 638-643
        • Kuipers H.
        • Wijnen J.A.
        • Hartgens F.
        • Willems S.M.
        Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver functions in body builders.
        Int J Sports Med. 1991; 12: 413-418
        • Nottin S.
        • Nguyen L.D.
        • Terbah M.
        • Obert P.
        Cardiovascular effects of androgenic anabolic steroids in male bodybuilders determined by tissue Doppler imaging.
        Am J Cardiol. 2006; 97: 912-915
        • Mottram D.
        • George A.J.
        Anabolic steroids.
        Baillieres Best Pract Res Clin Endocrinol Metab. 2000; 14: 55-69
        • Kennedy C.
        Myocardial infarction in association with misuse of anabolic steroids.
        Ulster Med J. 1993; 62: 174-176
        • Sachtleben T.
        • Berg K.E.
        • Elias B.A.
        • Cheatham J.P.
        • Felix G.L.
        • Hofschire P.J.
        The effects of anabolic steroids on myocardial structure and cardiovascular fitness.
        Med Sci Sport Exer. 1993; 25: 1240-1245
        • Urhausen A.
        • Holpes R.
        • Kindermann W.
        One- and two-dimensional echocardiography in bodybuilders using anabolic steroids.
        Eur J Appl Physiol. 1989; 58: 633-640
        • Sharma S.
        Athlete's heart—effect of age, sex, ethnicity and sporting discipline.
        Exp Physiol. 2003; 88: 665-669
        • Marsh J.
        • Lehmann M.H.
        • Ritchie R.H.
        • Gwathmey J.K.
        • Green G.E.
        • Schiebinger R.J.
        Androgen receptors mediate hypertrophy in cardiac myocytes.
        Circulation. 1998; 98: 256-261
        • Kuhn C.
        Anabolic steroids.
        Recent Prog Horm Res. 2002; 57: 411-434
        • Liu P.
        • Death A.K.
        • Handelsman D.J.
        Androgens and cardiovascular disease.
        Endocr Rev. 2003; 24: 313-340
        • Payne J.
        • Kotwinski P.J.
        • Montgomery H.E.
        Cardiac effects of anabolic steroids.
        Heart. 2004; 90: 473-475
        • Dickerman R.
        • Schaller F.
        • McConathy W.J.
        Left ventricular wall thickening does occur in elite power athletes with or without anabolic steroid use.
        Cardiology. 1998; 90: 145-148
        • Fisher A.G.
        • Adams T.D.
        • Yanowitz F.G.
        • Ridges J.D.
        • Orsmond G.
        • Nelson A.G.
        Noninvasive evaluation of world class athletes engaged in different modes of training.
        Am J Cardiol. 1989; 63: 337-341
        • Colan S.
        • Sanders S.P.
        • Borow K.M.
        Physiologic hypertrophy: effects on left ventricular systolic mechanics in athletes.
        J Am Coll Cardiol. 1987; 9: 776-783
        • D'Andrea A.
        • Limongelli G.
        • Caso P.
        • Sarubbi B.
        • Peitra A.D.
        • Brancaccio P.
        • Cice G.
        • Scherillo M.
        • Limongelli F.
        • Calabro R.
        Association between left ventricular structure and cardiac performance during effort in two morphological forms of athlete's heart.
        Int J Cardiol. 2002; 86: 177-184
        • Thompson F.
        • Sadaniantz A.
        • Cullinane E.M.
        • Bodziony K.S.
        • Catlin D.H.
        • Torek-Both G.
        • Douglas P.S.
        Left ventricular function is not impaired in weight lifters who use anabolic steroids.
        J Am Coll Cardiol. 1992; 19: 278-282
        • Chung T.
        • Kelleher S.
        • Liu P.Y.
        • Conway A.J.
        • Kritharides L.
        • Handelsman D.J.
        Effects of testosterone and nandrolone on cardiac function: a randomized, placebo-controlled study.
        Clin Endocrinol. 2007; 66: 235-245
        • Kennedy M.
        • Corrigan A.B.
        • Pilbeam S.T.
        Myocardial infarction and cerebral haemorrhage in a young body builder taking anabolic steroids.
        Aust N Z J Med. 1993; 23: 713
        • Hausmann R.
        • Hammer S.
        • Betz P.
        Performance enhancing drugs (doping agents) and sudden death—a case report and review of the literature.
        Int J Legal Med. 1998; 111: 261-264
        • Luke J.
        • Farb A.
        • Virmani R.
        • Sample R.H.
        Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: pathological and toxicological findings.
        J Forensic Sci. 1990; 35: 1441-1447
        • Angelilli A.
        • Katz E.S.
        • Goldenberg R.M.
        Cardiac arrest following anaesthetic induction in a world-class bodybuilder.
        Acta Cardiol. 2005; 60: 443-444
        • Wysoczanski M.
        • Rachko M.
        • Bergmann S.
        Acute myocardial infarction in a young man using anabolic steroids.
        Angiology. 2008; 59: 376-378
        • Fineschi V.
        • Riezzo I.
        • Centini F.
        • Silingardi E.
        • Licata M.
        • Beduschi G.
        • Karch S.B.
        Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders.
        Int J Legal Med. 2007; 121: 48-53
        • Sullivan M.L.
        • Martinez C.M.
        • Gennis P.
        • Gallagher E.J.
        The cardiac toxicity of anabolic steroids.
        Prog Cardiovasc Dis. 1998; 41: 1-15
        • Ferenchick G.
        Anabolic/androgenic steroid abuse and thrombosis: is there a connection?.
        Med Hypotheses. 1991; 35: 27-31
        • Roeggia M.
        • Heinz G.
        • Werba E.
        • Roeggla G.
        Cardiac tamponade in a 21-year-old body builder with anabolica abuse.
        Br J Clin Pract. 1996; 50: 411-412
        • Ferenchick G.
        • Adelman S.
        Myocardial infarction associated with anabolic steroid use in a previously healthy 37-year-old weight lifter.
        Am Heart J. 1992; 124: 507-508
        • Huie M.
        An acute myocardial infarction occurring in an anabolic steroid user.
        Med Sci Sport Exer. 1994; 26: 408-413
        • Fisher M.
        • Appleby M.
        • Rittoo D.
        • Cotter L.
        Myocardial infarction with extensive intracoronary thrombus induced by anabolic steroids.
        Br J Clin Pract. 1996; 50: 222-223
        • Furlanello F.
        • Serdoz L.V.
        • Cappato R.
        • De Ambroggi L.
        Illicit drugs and cardiac arrhythmias in athletes.
        Eur J Cardiovasc Prev Rehabil. 2007; 14: 487-494
        • Dickerman R.D.
        • Schaller F.
        • Prather I.
        • McConathy W.J.
        Sudden cardiac death in a 20-year-old bodybuilder using anabolic steroids.
        Cardiology. 1995; 86: 172-173
        • Saugy M.
        • Robinson N.
        • Saudan C.
        • Baume N.
        • Avois L.
        • Mangin P.
        Human growth hormone doping in sport.
        Br J Sport Med. 2006; 40: i35-i39
        • Jenkins P.
        Growth hormone and exercise.
        Clin Endocrinol. 1999; 50: 683-689
        • Jenkins P.
        Doping in sport.
        Lancet. 2002; 360: 99-100